Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic announced the appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024. Tardio, a former executive at Novartis and Biogen, brings extensive experience in MS drug commercialization. He will lead efforts to launch vidofludimus calcium, an oral treatment for relapsing and progressive MS.
Additionally, Werner Gladdines has been promoted to Chief Development Officer. He previously served as Vice President, Program Management & Clinical Development Operations. Gladdines will now assume greater strategic and operational responsibilities for Immunic's clinical operations.
Tardio's notable achievements include launching successful MS drugs and leading commercial businesses. His expertise is expected to significantly aid Immunic as it approaches the completion of phase 3 trials for vidofludimus calcium and prepares for potential partnerships.
Immunic (Nasdaq: IMUX), a biotechnology company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, announced its participation in key industry and scientific conferences in June 2024. The company will present at the BIO International Convention in San Diego, California, from June 3-6, with Jessica Breu, VP of Investor Relations and Communications, presenting on June 4 at 11:00 am PDT. Immunic's management will engage in partnering activities at this event. Additionally, Werner Gladdines, VP of Program Management and Clinical Development Operations, will join a panel discussion at the Pharmaceutical Contract Management Group (PCMG) Assembly in Den Haag, The Netherlands, from June 5-7. His panel, 'Spin the Wheel of Collaboration!', is scheduled for June 6 at 12:05 pm CEST.
Immunic, Inc. reported Q1 2024 financial results, highlighting a three-tranche private placement of up to $240 million to extend cash runway, received a fourth US patent for MS treatment, and is progressing with phase 3 ENSURE trials in RMS and phase 2 CALLIPER trial in PMS. The company aims to position vidofludimus calcium as the first oral treatment for MS, while also advancing IMU-856 for gastrointestinal disorders.
Immunic, Inc. (Nasdaq: IMUX) will be participating in various investor and scientific conferences in May, presenting data from clinical trials of their small molecule therapies targeting chronic inflammatory and autoimmune diseases. The conferences include Bio€quity Europe, Digestive Disease Week, The Consortium of Multiple Sclerosis Centers, and the National Congress of Neurology. Key presentations will focus on the phase 1b clinical trial of IMU-856 for celiac disease and the phase 2 CALLIPER trial of vidofludimus calcium for multiple sclerosis.
Immunic, Inc., a biotechnology company focused on developing small molecule therapies for chronic inflammatory and autoimmune diseases, is set to announce its financial results for the first quarter ending March 31, 2024, along with a corporate update on May 8, 2024. A webcast will be held at 8:00 am ET on the same day. Participants can register in advance on the company's website to join the webcast.
Immunic, Inc. (IMUX) announces publication of data from its phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (RRMS) in Neurology® Neuroimmunology & Neuroinflammation. The study shows that vidofludimus calcium suppresses MRI lesions by 76% to 78% compared to placebo, reduces disability worsening events, and displays a dose-dependent effect in RRMS patients. Immunic continues with phase 3 ENSURE trials in relapsing MS and phase 2 CALLIPER trial in progressive MS.
Summary not available.
Summary not available.
Summary not available.
Summary not available.